Search
CNS Pharmaceuticals Inc
CNSPAdd to Watchlist
5.070USD
+0.390+8.33%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
3.21MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+8.33%
5 Days
+27.39%
1 Month
-3.98%
6 Months
-4.34%
Year to Date
-3.43%
1 Year
-54.08%
Key Figures
5.020Open
5.070High
11.08KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.75%Turnover Ratio
4.680Prev. Close
4.655Low
46.75KTurnover
LossP/E Static
0.71P/B
0.00%Div Yield TTM
-179.17%ROA
13.20052wk High
1.34Volume Ratio
-14.86MNet Profit
632.52KShares
-24.1215EPS TTM
0.88Beta
-298.64%ROE
1.90052wk Low
8.87%Amplitude
--Gross Margin
3.21MMarket Cap
-1.83Reward/Risk
6.22%Risk Rate
TradingKey Stock Score
No stock score available due to insufficient data.
CNS Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CNS Pharmaceuticals Inc Info
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. The Company's drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. TPI 287 has shown the potential to cross the blood-brain barrier and treat central nervous system (CNS) tumors.
Ticker SymbolCNSP
CompanyCNS Pharmaceuticals Inc
CEOClimaco (John Michael)
Websitehttps://cnspharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+4.11%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of CNS Pharmaceuticals Inc (CNSP)?
The current price of CNS Pharmaceuticals Inc (CNSP) is 5.07.
What is the symbol of CNS Pharmaceuticals Inc?
The ticker symbol of CNS Pharmaceuticals Inc is CNSP.
What is the 52-week high of CNS Pharmaceuticals Inc?
The 52-week high of CNS Pharmaceuticals Inc is 13.20.
What is the 52-week low of CNS Pharmaceuticals Inc?
The 52-week low of CNS Pharmaceuticals Inc is 1.90.
What is the market capitalization of CNS Pharmaceuticals Inc?
The market capitalization of CNS Pharmaceuticals Inc is 3.21M.
Is CNS Pharmaceuticals Inc (CNSP) currently rated as Buy, Hold, or Sell?
According to analysts, CNS Pharmaceuticals Inc (CNSP) has an overall rating of Buy, with a price target of 10.00.
What is the Earnings Per Share (EPS TTM) of CNS Pharmaceuticals Inc (CNSP)?
The Earnings Per Share (EPS TTM) of CNS Pharmaceuticals Inc (CNSP) is -35.75.